Regimen Reference Order – THOR - durvalumab

ARIA: LUNG – [durvalumab q 14 days]
LUNG – [durvalumab q 28 days]

Planned Course: **Every 14 days for one year (26 cycles total)**
OR
Every 28 days for one year (13 cycles total)

Indication for Use: **Non-Small Cell Lung Cancer, Stage III after concurrent chemotherapy with radiation; Adjuvant**

Drug Alert: Immune Checkpoint Inhibitor

CVAD: At Provider's Discretion

Proceed with treatment if:

- ***ANC equal to or greater than 1.5 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L***
- ***AST/ALT less than 3 times the upper limit of normal***
- ***Total bilirubin less than 1.5 times the upper limit of normal***
- ***Creatinine clearance greater than 30 mL/minute***
  - ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – THOR - durvalumab

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
durvalumab	10 mg/kg (every 14 days) **OR**	IV in 250 mL normal saline over 60 minutes *Use 0.2 or 0.22 micron filter*
	20 mg/kg (every 28 days)	IV in 250 mL normal saline over 60 minutes *Use 0.2 or 0.22 micron filter*

Maximum durvalumab dose is 750 mg (every 14 days) or 1500 mg (every 28 days)
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See THOR DSG – Dose Banding Document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order**'

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin, glucose and TSH as per Physician Orders
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Patient should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
    - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted

ADDITIONAL INFORMATION

- durvalumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated